Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy

Joseph D Butner; Maguy Farhat; Vittorio Cristini; Caroline Chung; Zhihui Wang

doi:10.1016/j.xpro.2022.101886

Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy

STAR Protoc. 2022 Dec 16;3(4):101886. doi: 10.1016/j.xpro.2022.101886. Epub 2022 Nov 30.

Authors

Joseph D Butner¹, Maguy Farhat², Vittorio Cristini³, Caroline Chung⁴, Zhihui Wang⁵

Affiliations

¹ Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA. Electronic address: jbutner@houstonmethodist.org.
² Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
³ Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA; Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA; Physiology, Biophysics, and Systems Biology Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
⁴ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: cchung3@mdanderson.org.
⁵ Mathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA; Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA; Department of Medical Education, Texas A&M University School of Medicine, Bryan, TX 77807, USA. Electronic address: zwang@houstonmethodist.org.

Abstract

This protocol describes the application of a mechanistic mathematical model of immune checkpoint inhibitor (ICI) immunotherapy to patient tumor imaging data for predicting solid tumor response and patient survival under ICI intervention. We describe steps for data collection and processing, data pipelines, and approaches to increase precision. The protocol is highly predictive as early as the first restaging after treatment start and can be used with standard-of-care imaging measures. For complete details on the use and execution of this protocol, please refer to Butner et al. (2020)¹ and Butner et al. (2021).².

Keywords: Biotechnology and bioengineering; Cancer; Health Sciences; Immunology; Systems biology.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Data Collection
Humans
Immune Checkpoint Inhibitors* / pharmacology
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy*

Substances

Immune Checkpoint Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding